Bruce Booth Sells 16,740 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 16,740 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $35.45, for a total transaction of $593,433.00. Following the completion of the transaction, the director now directly owns 803,792 shares in the company, valued at $28,494,426.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kymera Therapeutics Price Performance

NASDAQ:KYMR opened at $33.29 on Monday. Kymera Therapeutics, Inc. has a fifty-two week low of $9.60 and a fifty-two week high of $45.31. The stock has a market capitalization of $2.04 billion, a PE ratio of -13.26 and a beta of 2.25. The business’s 50-day simple moving average is $34.99 and its 200-day simple moving average is $33.67.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.04. Kymera Therapeutics had a negative return on equity of 31.92% and a negative net margin of 194.67%. The business had revenue of $10.30 million for the quarter, compared to analysts’ expectations of $14.24 million. During the same quarter in the previous year, the business posted ($0.70) EPS. Kymera Therapeutics’s revenue for the quarter was up 8.4% on a year-over-year basis. On average, research analysts expect that Kymera Therapeutics, Inc. will post -2.86 earnings per share for the current year.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors have recently modified their holdings of the business. Quest Partners LLC bought a new position in shares of Kymera Therapeutics during the 4th quarter valued at about $78,000. Comerica Bank raised its position in Kymera Therapeutics by 13.7% in the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after buying an additional 400 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in Kymera Therapeutics by 7.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock valued at $164,000 after buying an additional 295 shares during the last quarter. Virtu Financial LLC acquired a new stake in Kymera Therapeutics in the 1st quarter valued at approximately $207,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Kymera Therapeutics by 352.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,423 shares of the company’s stock valued at $164,000 after buying an additional 5,002 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on KYMR shares. Oppenheimer cut their price target on Kymera Therapeutics from $53.00 to $52.00 and set an “outperform” rating on the stock in a research note on Friday, May 3rd. HC Wainwright restated a “buy” rating and set a $46.00 target price on shares of Kymera Therapeutics in a report on Monday, June 3rd. Piper Sandler raised their target price on Kymera Therapeutics from $39.00 to $56.00 and gave the stock an “overweight” rating in a report on Tuesday, February 27th. Truist Financial raised their target price on Kymera Therapeutics from $41.00 to $54.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Finally, Stifel Nicolaus raised their target price on Kymera Therapeutics from $35.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, February 23rd. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Kymera Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $42.70.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.